Patents by Inventor Anthony S. Muerhoff
Anthony S. Muerhoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11421023Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.Type: GrantFiled: April 17, 2019Date of Patent: August 23, 2022Assignee: ABBOTT LABORATORIESInventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
-
Patent number: 11340230Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).Type: GrantFiled: October 15, 2020Date of Patent: May 24, 2022Assignee: Abbott LaboratoriesInventors: Anthony S. Muerhoff, John C. Prostko, Christopher C. Marohnic
-
Publication number: 20220043003Abstract: The present disclosure relates to methods of detecting a protein from the SARS-CoV-2 virus, or a fragment thereof, in a sample obtained from a subject using a first antibody or antigen-binding fragment thereof that binds to a protein from the SARS-CoV-2 virus, or a fragment thereof, and a second antibody or antigen-binding fragment thereof which binds to a protein from the SARS-CoV-2 virus, or a fragment thereof.Type: ApplicationFiled: August 4, 2021Publication date: February 10, 2022Inventors: Lawrence B. Blyn, Mijung Ji, Stephen Kovacs, Anthony S. Muerhoff, Stacey P. Huth, Carsten Buenning, Tao Xin, Donabel Roberts, Sung Hee Kim, Sang Yong Park, Robert N. Ziemann
-
Patent number: 11022598Abstract: Methods, devices, and systems for analyte analysis using a nanopore are disclosed. The methods, devices, and systems utilize a first and a second binding member that each specifically bind to an analyte in a biological sample. The method further includes detecting and/or counting a cleavable tag attached to the second binding member and correlating the presence and/or the number of tags to presence and/or concentration of the analyte. Certain aspects of the methods do not involve a tag, rather the second binding member may be directly detected/quantitated. The detecting and/or counting may be performed by translocating the tag/second binding member through a nanopore. Devices and systems that are programmed to carry out the disclosed methods are also provided.Type: GrantFiled: October 3, 2017Date of Patent: June 1, 2021Assignee: ABBOTT LABORATORIESInventors: Jeffrey B. Huff, Mark A. Hayden, Peter J. Karabatsos, Andrew S. Schapals, Anthony S. Muerhoff, M. Felicia Bogdan, Thomas Leary, Shelley R. Holets-McCormack, Sophie Laurenson, Andrew T. Fischer, Richard Haack, Stefan Hershberger, Dustin House, Lei Qiao, M. Shawn Murphy, Mark R. Pope, Edna M. Prieto-Ballengee, QiaoQiao Ruan, Pathik Soni, Sergey Tetin, Lyle Yarnell
-
Publication number: 20210041442Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).Type: ApplicationFiled: October 15, 2020Publication date: February 11, 2021Inventors: Anthony S. Muerhoff, John C. Prostko, Christopher C. Marohnic
-
Patent number: 10816551Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).Type: GrantFiled: September 5, 2018Date of Patent: October 27, 2020Assignee: Abbott LaboratoriesInventors: Anthony S. Muerhoff, John C. Prostko, Christopher C. Marohnic
-
Publication number: 20200256843Abstract: Methods, devices, and systems for analyte analysis using a nanopore are disclosed. The methods, devices, and systems utilize a first and a second binding member that each specifically bind to an analyte in a biological sample. The method further includes detecting and/or counting a cleavable tag attached to the second binding member and correlating the presence and/or the number of tags to presence and/or concentration of the analyte. Certain aspects of the methods do not involve a tag, rather the second binding member may be directly detected/quantitated. The detecting and/or counting may be performed by translocating the tag/second binding member through a nanopore. Devices and systems that are programmed to carry out the disclosed methods are also provided.Type: ApplicationFiled: May 1, 2020Publication date: August 13, 2020Applicant: ABBOTT LABORATORIESInventors: Jeffrey B. Huff, Mark A. Hayden, Peter J. Karabatsos, Andrew S. Schapals, Anthony S. Muerhoff, M. Felicia Bogdan, Thomas Leary, Shelley R. Holets-McCormack, Sophie Laurenson, Andrew T. Fischer, Richard Haack, Stefan Hershberger, Dustin House, Lei Qiao, M. Shawn Murphy, Mark R. Pope, Edna M. Prieto-Ballengee, QiaoQiao Ruan, Pathik Soni, Sergey Tetin, Lyle Yarnell
-
Publication number: 20190315844Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.Type: ApplicationFiled: April 17, 2019Publication date: October 17, 2019Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
-
Patent number: 10308709Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.Type: GrantFiled: October 11, 2016Date of Patent: June 4, 2019Assignee: Abbott LaboratoriesInventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
-
Publication number: 20190064169Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).Type: ApplicationFiled: September 5, 2018Publication date: February 28, 2019Inventors: Anthony S. Muerhoff, John C. Prostko, Christopher C. Marohnic
-
Patent number: 10088483Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).Type: GrantFiled: October 28, 2015Date of Patent: October 2, 2018Assignee: Abbott LaboratoriesInventors: Anthony S. Muerhoff, John Prostko, Chris Marohnic
-
Publication number: 20180188230Abstract: Methods, devices, and systems for analyte analysis using a nanopore are disclosed. The methods, devices, and systems utilize a first and a second binding member that each specifically bind to an analyte in a biological sample. The method further includes detecting and/or counting a cleavable tag attached to the second binding member and correlating the presence and/or the number of tags to presence and/or concentration of the analyte. Certain aspects of the methods do not involve a tag, rather the second binding member may be directly detected/quantitated. The detecting and/or counting may be performed by translocating the tag/second binding member through a nanopore. Devices and systems that are programmed to carry out the disclosed methods are also provided.Type: ApplicationFiled: October 3, 2017Publication date: July 5, 2018Applicant: ABBOTT LABORATORIESInventors: Jeffrey B. Huff, Mark A. Hayden, Peter J. Karabatsos, Andrew S. Schapals, Anthony S. Muerhoff, Felicia Bogdan, Thomas Leary, Shelley R. Holets-McCormack, Sophie Laurenson, Andrew T. Fischer, Richard Haack, Stefan Hershberger, Dustin House, Lei Qiao, M. Shawn Murphy, Mark R. Pope, Edna M. Prieto-Ballengee, QiaoQiao Ruan, Pathik Soni, Sergey Tetin, Lyle Yarnell
-
Publication number: 20180095067Abstract: Integrated microfluidic and analyte detection devices are disclosed, along with methods of detecting target analytes. Digital microfluidic and analyte detection devices include a first substrate and a second substrate aligned generally parallel to each other to define a gap therebetween, the first substrate including a plurality of electrodes to generate electrical actuation forces on a liquid droplet disposed in the gap; at least one reagent disposed on at least one of the first substrate or the second substrate and configured to be carried by the liquid droplet; and an analyte detection device in fluid communication with the gap, wherein the plurality of electrodes are configured to move the liquid droplet towards the analyte detection device.Type: ApplicationFiled: October 3, 2017Publication date: April 5, 2018Applicant: Abbott LaboratoriesInventors: Jeffrey B. Huff, Mark A. Hayden, Peter J. Karabatsos, Andrew S. Schapals, Anthony S. Muerhoff, Felicia Bogdan, Thomas Leary, Shelley R. Holets-McCormack, Sophie Laurenson, Andrew T. Fischer, Richard Haack, Stefan Hershberger, Dustin House, Lei QIAO, M. Shawn Murphy, Mark R. Pope, Edna M. Prieto-Ballengee, QiaoQiao Ruan, Pathik Soni, Sergey Tetin, Lyle Yarnell, John M. Robinson
-
Publication number: 20170096477Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.Type: ApplicationFiled: October 11, 2016Publication date: April 6, 2017Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
-
Patent number: 9469686Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.Type: GrantFiled: March 15, 2013Date of Patent: October 18, 2016Assignee: ABBOTT LABORATORIESInventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
-
Publication number: 20160131653Abstract: The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).Type: ApplicationFiled: October 28, 2015Publication date: May 12, 2016Inventors: Anthony S. Muerhoff, John Prostko, Chris Marohnic
-
Publication number: 20140024050Abstract: The present invention relates to antibodies or binding proteins which bind to PIVKA II and may be used, for example, in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.Type: ApplicationFiled: February 14, 2013Publication date: January 23, 2014Applicant: ABBOTT LABORATORIESInventors: TORU YOSHIMURA, Sharmila Manoj, Bailin Tu, Anthony S. Muerhoff
-
Publication number: 20120329176Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: ABBOTT LABORATORIESInventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
-
Patent number: 8268981Abstract: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.Type: GrantFiled: March 4, 2009Date of Patent: September 18, 2012Assignee: Abbott LaboratoriesInventors: Larry G. Birkenmeyer, Anthony S. Muerhoff, Suresh M. Desai, George J. Dawson, Bruce J. Dille
-
Publication number: 20110311572Abstract: The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of Plasmodium vivax, and methods of using these polynucleotides and polypeptides in the detection of P. vivax antibodies or anti-P. vivax antibodies in a subject. The invention finds particular useful application in identifying recent exposure to P. vivax.Type: ApplicationFiled: August 29, 2011Publication date: December 22, 2011Applicant: ABBOTT LABORATORIESInventors: Larry G. Birkenmeyer, Ruthie E. Coffey, George J. Dawson, Suresh M. Desai, Bruce J. Dille, Anthony S. Muerhoff